Amgen has entered into a Bridge Credit Agreement, dated December 12, 2022, for an aggregate amount of $28.5 billion, by and among Amgen, Citibank N.A., as administrative agent, Bank of America, N.A., as syndication agent, and Citibank, N.A.The Acquisition values the entire issued and to be issued ordinary share capital of the Company at approximately $27.8 billion on a fully diluted basis and implies an enterprise value of approximately $28.3 billion.a premium of approximately 19.7% to the closing price of $97.29 per Company Share on December 9, 2022.a premium of approximately 47.9% to the closing price of $78.76 per Company Share on Novem(being the last closing price per Company Share prior to the Company's issuance of an announcement of a possible offer under Rule 2.4 of the Irish Takeover Rules) and.Under the terms of the Acquisition, each Company Shareholder at the Scheme Record Time will be entitled to receive: (" Amgen") are pleased to announce that they have reached agreement on the terms of a cash offer for the Company by Pillartree Limited (" Acquirer Sub"), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company.
HORIZON THERAPEUTICS CEO TRIAL
Freising.Clinical Trial Diversity and RepresentationĬlinical Trial Transparency, Data Sharing and Disclosure PracticesĪdverse Event and Product Complaint ReportingĮnvironmental, Social & Governance Report 2022Įnvironment, Social and Governance StrategyĬommunity Investment and Amgen Foundation "Press Release: Horizon Pharma plc and XL-protein GmbH Have Entered Into a Collaboration Agreement on a Potential Next-Generation Biologic for Uncontrolled Gout Using PASylation Technology". "Press Release: Advicenne Appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs". "Press Release: FDA Approves Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)". to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio". "Press Release: Horizon Therapeutics plc to Acquire Viela Bio, Inc. Amgen Inc to Acquire Horizon Therapeutics plc". More documents for Horizon Therapeutics (Group) (Tim) (Horizon Pharma 201003– CEO before IDM Pharma CEO before NeoPharm + Abbott) The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians while taking advantage of its commercial strengths and the infrastructure the Company has put in place.
The Company markets DUEXIS® and RAYOS®/LODOTRA® and will market VIMOVO®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists.
0 kommentar(er)
